Viridian Therapeutics, Inc.\DE (VRDN)
Viridian Therapeutics, Inc.\DE (VRDN) from its SEC filings: 2025 revenue $70.8 million (+23360% vs the year before), net margin -484%, free cash flow -$276.9 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $70.8 million |
| Revenue growth | +23360% |
| Net income | -$342.6 million |
| Net margin | -483.6% |
| Free cash flow | -$276.9 million |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +279% |
| Cash | $24.9 million |
| Long-term debt | $20.9 million |
| Share count, 1 year | +39% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.